These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 32416056)

  • 1. Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.
    Sabry M; Lowdell MW
    Stem Cells Transl Med; 2020 Sep; 9(9):974-984. PubMed ID: 32416056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK cell-based cancer immunotherapy: from basic biology to clinical application.
    Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
    Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cells and cancer therapy, what we know and where we are going.
    Ghaemdoust F; Keshavarz-Fathi M; Rezaei N
    Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular therapy of cancer with natural killer cells-where do we stand?
    Klingemann HG
    Cytotherapy; 2013 Oct; 15(10):1185-94. PubMed ID: 23768925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memory-like natural killer cells for cancer immunotherapy.
    Gang M; Wong P; Berrien-Elliott MM; Fehniger TA
    Semin Hematol; 2020 Oct; 57(4):185-193. PubMed ID: 33256911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving natural killer cell cancer immunotherapy.
    Berrien-Elliott MM; Romee R; Fehniger TA
    Curr Opin Organ Transplant; 2015 Dec; 20(6):671-80. PubMed ID: 26414502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bringing natural killer cells to the clinic: ex vivo manipulation.
    Childs RW; Berg M
    Hematology Am Soc Hematol Educ Program; 2013; 2013(1):234-46. PubMed ID: 24319186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
    Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
    Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging natural killer cells for cancer immunotherapy.
    Grossenbacher SK; Aguilar EG; Murphy WJ
    Immunotherapy; 2017 May; 9(6):487-497. PubMed ID: 28472904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell therapies.
    Vivier E; Rebuffet L; Narni-Mancinelli E; Cornen S; Igarashi RY; Fantin VR
    Nature; 2024 Feb; 626(8000):727-736. PubMed ID: 38383621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination.
    van Beek JJ; Wimmers F; Hato SV; de Vries IJ; Sköld AE
    Crit Rev Immunol; 2014; 34(6):517-36. PubMed ID: 25597314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential therapeutic role of natural killer cells in cancer.
    Woan K; Reddy V
    Expert Opin Biol Ther; 2007 Jan; 7(1):17-29. PubMed ID: 17150016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
    Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
    Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.
    Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Carnevale-Schianca F; Aglietta M; Sangiolo D
    Anticancer Agents Med Chem; 2014 Feb; 14(2):211-22. PubMed ID: 24237224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
    Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
    Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
    Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
    Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy.
    Noh JY; Yoon SR; Kim TD; Choi I; Jung H
    J Immunol Res; 2020; 2020():2045860. PubMed ID: 32377528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.